Amneal Lanreotide Approved by US FDA

Amneal launches first CGT‑designated U.S. generic lanreotide — what NET patients need to know

Amneal has launched the first Competitive Generic Therapy (CGT)‑designated U.S. generic for lanreotide, a major milestone in a market long dominated by Ipsen’s Somatuline® Depot. The product — lanreotide injection 120 mg/0.5 mL in a sterile single‑dose prefilled syringe — is FDA‑approved as a fully substitutable generic and is now commercially available through U.S. specialty distribution. Amneal announced the approval here.

1. Why Amneal’s approval matters

Amneal’s lanreotide was approved through the FDA’s Abbreviated New Drug Application (ANDA) pathway — the strict 505(j) route used for true generics of an already‑approved Reference Listed Drug (Somatuline® Depot). Under an ANDA, manufacturers do not repeat clinical trials; instead, they must prove bioequivalence and therapeutic equivalence, demonstrating that the generic has the same active ingredient, strength, dosage form, route of administration, and in‑body performance as the brand‑name product. This is the highest level of ‘sameness’ the FDA requires for a generic injectable.

Amneal also received Competitive Generic Therapy (CGT) designation, granted only in markets with limited competition. CGT status signals FDA confidence in the product and typically accelerates payer uptake. Together, ANDA approval plus CGT designation provide strong reassurance that Amneal’s lanreotide is as similar to Somatuline® Depot as a generic can be under the FDA system.

2. Prescribing information

For those wanting to verify equivalence directly, the FDA‑approved prescribing information — appears to be structurally identical to Ipsen’s but listing Amneal as manufacturer — is available here: Amneal Lanreotide PI

3. What about Cipla?

A generic from Cipla/InvaGen, entered the market prior to Amneal but without CGT designation. Cipla originally secured approval via a 505(b)(2) NDA before later obtaining a full ANDA, giving it standard generic status. Its device closely resembles Ipsen’s syringe, reinforcing supply and competition, but unlike Amneal it does not have CGT status. Cipla is still working through FDA‑identified manufacturing issues at one of its facilities. While this does not block its lanreotide approval, it is relevant context for patients and clinics comparing generics.

4. Device visibility — an important missing piece

As of now, Amneal has not released any images of its injection device nor does it appear to have a dedicated Amneal Lanreotide website providing physician and patient support. I will continue to look for those. For NET patients and nurses who rely heavily on device stability, plunger feel, and injection ergonomics. However, because of the CGT rubber stamp, Amneal’s syringe must meet FDA performance‑equivalence standards. I will update this blog in due course.

5. Cost expectations — a realistic note

Many will assume that the arrival of generics will immediately reduce lanreotide costs. I really hope it will for my fellow US patients but this is not necessarily going to happen. In complex specialty injectables, pricing is shaped by contracts, specialty‑pharmacy distribution, and market dynamics that do not always respond quickly to competition. Amneal’s approval increases choice and may improve access, but patients should not assume rapid or dramatic reductions in out‑of‑pocket costs.

6. Summary

Amneal’s CGT‑designated ANDA approval is the key milestone, confirming a fully substitutable generic lanreotide for NET and acromegaly patients. Cipla’s ANDA did add depth to the market, but Amneal’s entry is an important and timely headline. As this news broke whilst I was on holiday, I had to circumvent my blog process, so you may wish to review the comments from my Facebook pages here and here.

See also:

My experience with Lanreotide.

Generics

Injection Devices

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.